Literature DB >> 2863323

Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.

D Clark, S Hjorth, A Carlsson.   

Abstract

In a companion article, we extensively reviewed the pharmacological actions of the enantiomers of the dopamine analogue 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP. The profiles of action exhibited by transdihydrolisuride (TDHL) and the trans-fused 7-OH-1,2,3,4,4a,5,6,10-octahydrobenzo(f)quinoline (HW 165) were also described. These latter agents, along with (-)-3-PPP, exert a variety of effects at different DA receptors depending on the anatomical location of these receptor sites and the experimental conditions. In the first part of the present article, it is suggested that the intrinsic activity of these agents in different pharmacological models is dependent on the responsiveness of the relevant DA-receptors which, in turn, is related to the degree of previous agonist occupancy of these sites. In situations where these agents exhibit partial agonist activity, their pharmacological effect is also dependent on the relative concentrations of drug and endogenous DA competing for common receptor sites. A number of theoretical implications will be discussed relevant to the suggestion that DA receptors exist in various adaptational states which can influence drug action. In the second part of this review, we will consider the behavioural profile exhibited by (-)-3-PPP in relation to that observed with classical DA antagonists. In addition, the potential clinical application of (-)-3-PPP and similar-acting agents will be discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863323     DOI: 10.1007/bf01252236

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  48 in total

1.  Neuroleptic antagonism of the motor inhibitory effects of apomorphine within the nucleus accumbens: drug interaction at presynaptic receptors?

Authors:  B Costall; D H Fortune; S C Hui; R J Naylor
Journal:  Eur J Pharmacol       Date:  1980-05-16       Impact factor: 4.432

2.  Effects of thioridazine on apomorphine-elicited stereotypic behavior and motor activity.

Authors:  H Lai; M A Carino; R Sperry; A Horita
Journal:  Pharmacol Biochem Behav       Date:  1980-09       Impact factor: 3.533

3.  Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.

Authors:  M J Bannon; E B Bunney; J R Zigun; L R Skirboll; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

Review 4.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

5.  Neuroleptic-induced acute dyskinesias in rhesus monkeys.

Authors:  R D Porsolt; M Jalfre
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 6.  Dendritic release of dopamine in the substantia nigra.

Authors:  A Cheramy; V Leviel; J Glowinski
Journal:  Nature       Date:  1981-02-12       Impact factor: 49.962

7.  Are presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in the rabbit caudate nucleus pharmacologically different?

Authors:  I Helmreich; W Reimann; G Hertting; K Starke
Journal:  Neuroscience       Date:  1982-06       Impact factor: 3.590

8.  Dopamine receptor binding in bovine intermediate lobe pituitary membranes.

Authors:  D R Sibley; I Creese
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

9.  Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects.

Authors:  J Liebman; R Neale
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine.

Authors:  P J Fray; B J Sahakian; T W Robbins; G F Koob; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  31 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  Effects of low, autoreceptor selective doses of dopamine agonists on the discriminative cue and locomotor hyperactivity produced by d-amphetamine.

Authors:  L Furmidge; Z Y Tong; N Petry; D Clark
Journal:  J Neural Transm Gen Sect       Date:  1991

4.  (+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors.

Authors:  K Svensson; S Hjorth; D Clark; A Carlsson; H Wikström; B Andersson; D Sanchez; A M Johansson; L E Arvidsson; U Hacksell
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

5.  Effects of B-HT 920 on nigrostriatal and mesolimbic dopamine systems in normosensitive and supersensitive rats.

Authors:  P B Clarke; K J Wyder; A Jakubovic; H C Fibiger
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

6.  Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK&F 38393.

Authors:  S Hjorth; A Carlsson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 7.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

9.  Pharmacologic properties of (-)-3PPP (preclamol) in man.

Authors:  C A Tamminga; N G Cascella; R A Lahti; M Lindberg; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum.

Authors:  A Carlsson; L Löfberg
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.